Drugs / ABBV-576
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05530278 | Sep → Nov 2022 | — | AbbVie | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04853368 | Sep 2021 → Jun 2023 | cystic fibrosis | AbbVie | Terminated | Mixed Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-576 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05530278 ↗ |
| Route | Oral | “Oral capsules” NCT04853368 ↗ |